TheraVet SA (ALVET.PA)
| Previous close | 0.6960 |
| Open | 0.6960 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.6620 - 0.6960 |
| 52-week range | 0.6620 - 2.4000 |
| Volume | |
| Avg. volume | 9,307 |
| Market cap | 2.134M |
| Beta (5Y monthly) | -0.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireTheraVet reports Full-Year 2023 Financial Results and Provides the Preparatory Documents for the General Meeting of June 6th, 2024
GOSSELIES, Belgium, April 23, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET) (Paris:ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announces its Full-Year results for the year to December 31, 2023.
Business WireTheraVet Reports 2023 Full Year and 2024 First Quarter Revenues
GOSSELIES, Belgium, April 10, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, reports its 2023 full year and 2024 first quarter revenues.
Business WireTheraVet : BIOCERA-VET® is Now Available for the Management of Dental and Orthopedics Conditions in Horses
GOSSELIES, Wallonia, Belgium, March 13, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the launch of BIOCERA-VET® Equine in countries already covered by the Company.
